Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01450514
Other study ID # PNB02-C201
Secondary ID 2011-004494-81
Status Completed
Phase Phase 2
First received October 7, 2011
Last updated November 18, 2014
Start date March 2012
Est. completion date December 2012

Study information

Verified date November 2014
Source PharmaNeuroBoost N.V.
Contact n/a
Is FDA regulated No
Health authority Belgium: Federal Agency for Medicinal Products and Health Products
Study type Interventional

Clinical Trial Summary

This Phase I/IIa Proof-of-Concept (PoC) trial is designed to assess the effect of adding a single and repeated low dose (15mg/d) of pipamperone (PIP) for 6 weeks to stable treatment with an effective dose of risperidone (RIS) or paliperidone (PAL) on functional MRI tests and clinical outcome of chronic schizophrenic patients with residual, so-called 'positive' symptoms, as well as on cognition, motivation, subjective well-being of patients, negative symptoms, general psychopathological symptoms and safety/tolerability.


Description:

This exploratory study of 7 weeks was intended to be performed in 40 to 60 patients in up to 10 centers in Belgium. In a subset of patients, the 6-week treatment phase will be preceded by a single-dose cross-over phase with 1 week of wash-out. While the objective of the study, due to its exploratory design, is to assess any effect of the study medication on MRI or clinical outcome, the study medication is expected to improve the residual (remaining) positive symptom(s) of patients. In addition, genetic and pharmacokinetic testing may be performed to learn more about the disorder and its treatment.


Recruitment information / eligibility

Status Completed
Enrollment 7
Est. completion date December 2012
Est. primary completion date November 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Patient is informed and given ample time and opportunity to think about her/his participation and has given her/his written informed consent.

- Patient understands the investigational nature of the trial and is willing and able to comply with the trial requirements.

- Patient is male or female, aged 18-65 years.

- Patients has Schizophrenia or Schizoaffective disorder according to the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV-R criteria. Diagnosis will be confirmed by the Mini International Neuropsychiatric Interview (MINI)

- Patient is being treated during at least 12 weeks with a stable dosage of either risperidone depot of 12.5-50mg IM every 2 weeks, paliperidone depot of 25-100mg IM every 4 weeks, risperidone oral administration of 2-6 mg/d, or paliperidone oral administration of 4-12 mg/d

- Patient has a CGI-S score of 3 (mildly ill) or more at baseline.

- Patient has a score of 4 or more on at least 1 item of the positive PANSS subscale (residual symptoms).

Exclusion Criteria:

- Acute exacerbation of schizophrenic or schizoaffective disorder during the past 12 weeks.

- Documented debility or an IQ below 85.

- Comorbid axis 1 conditions (including anxiety disorders, eating disorders, impulse control disorders) requiring drug treatment over the previous 12 weeks.

- Patient has taken, in the past 6 weeks prior to randomization, any newly initiated psychoactive drug.

- Patient was withdrawn from psychoactive drug treatment in the past week or within a period shorter than 5x the elimination half-life of any psychoactive drug. Withdrawal of any prior antipsychotic treatment should not have occurred within 6 weeks prior to baseline.

- Concomitant treatment with any additional antipsychotic drug at a therapeutic dosage, diuretics, QT prolongation drugs, or dopamine agonists.

- Formal cognitive psychotherapy initiated during study treatment or within 6 weeks prior to randomization.

- Patient has any other medical or psychiatric condition, which in the opinion of the investigator, can jeopardize or would compromise the patient's ability to participate in this trial or that would interfere with trial assessments.

- Patient with a DSM-IV alcohol or substance dependence diagnosis (within the last 6 months), an alcohol or substance abuse diagnosis (within the last month) or having a positive standard screen for alcohol or drugs (including benzodiazepines and opioids).

- 'Any concomitant psychoactive treatment (including psychotherapy)' or 'Patient received, in the 6 weeks prior to randomization any newly prescribed psychoactive drug'.

- Patient is pregnant, nursing, or is a woman of child-bearing potential who is not surgically sterile, 2 years postmenopausal, or who does not consistently use 2 combined effective methods of contraception (including at least 1 barrier method), unless sexually abstinent.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Intervention

Drug:
Pipamperone
15 mg PIP once daily per os on top of continued stable treatment with RIS or PAL
Placebo
matching placebo sugar pill once daily per os on top of continued stable treatment with RIS or PAL

Locations

Country Name City State
Belgium University Psychiatric Institute Sint-Jozef Kortenberg

Sponsors (1)

Lead Sponsor Collaborator
PharmaNeuroBoost N.V.

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline in functional MRI tests MRI = Magnetic Resonance Imaging Functional tests performed during MRI include the N-Back Test and the Monetary Incentive Delay (MID) Task Test 1 day, 2 weeks and 6 weeks after study treatment start No
Secondary Change from baseline in residual PANSS item(s) PANSS = Positive and Negative Syndrome Scale 2 weeks and 6 weeks after study treatment start No
Secondary Change from baseline in SWN score and subitem scores SWN = Subjective Well-being under Neuroleptics questionnaire 2 weeks and 6 weeks after study treatment start No
Secondary Change from baseline in IMI-SR score and subitem scores IMI-SR = Intrinsic Motivation Inventory for Schizophrenia Research (questionnaire) 2 weeks and 6 weeks after study treatment start No
Secondary CGI-I score CGI-I = Clinical Global Impression if Improvement 2 weeks and 6 weeks after study treatment start No
Secondary Change from baseline in BARS total and subitem scores BARS = Barnes Akathisia Rating Scale 6 weeks after study treatment start Yes
Secondary Change from baseline in BACS score and subitem scores BACS = Brief Assessment of Cognition Scale 1 day, 2 weeks and 6 weeks after study treatment start No
See also
  Status Clinical Trial Phase
Completed NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) Phase 3
Completed NCT04284813 - Families With Substance Use and Psychosis: A Pilot Study N/A
Completed NCT01878513 - Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis N/A
Recruiting NCT05030272 - Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings N/A
Recruiting NCT04298450 - ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention N/A
Not yet recruiting NCT04551027 - Assessing the Effect of Compensatory Cognitive Intervention Among People With Severe Mental Illness N/A
Completed NCT02901587 - Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder Phase 1
Terminated NCT02796144 - MEtformin and Lorcaserin for WeighT Loss in Schizophrenia Phase 4
Completed NCT02160249 - RISE (Rehabilitation Intervention for People With Schizophrenia in Ethiopia) N/A
Recruiting NCT02986490 - Magnesium Variations and Cardiometabolic Risk in Patients With Antipsychotic Drugs N/A
Completed NCT02091388 - Bioavailability of LY03004 and Risperdal® Consta® Phase 1
Terminated NCT02234752 - Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia Phase 2
Completed NCT02417142 - Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia Phase 4
Completed NCT01975584 - Neuroendocrine and Immune Response to Stress in Schizophrenia N/A
Completed NCT01945333 - Personalized and Scalable Cognitive Remediation Approaches N/A
Terminated NCT02149823 - Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations Phase 1
Completed NCT01992393 - Targeted Self-Management for Epilepsy and Serious Mental Illness (TIME) N/A
Completed NCT01683539 - Understanding How Cognitive Remediation Works N/A
Completed NCT01658150 - Evaluating Isradipine for Cognitive Enhancement in Schizophrenia and Schizoaffective Disorder N/A
Completed NCT01292577 - Adapted Cognitive/Affective Remediation for Cannabis Misuse in Schizophrenia Phase 1/Phase 2